# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	)	
Schellenberger, et al.	)	Group Art Unit:
	)	
Serial No.: 09/975,139	)	Examiner: Unassigned
	)	
Filed: October 10, 2001	)	
	)	
For: Information Rich Libraries	)	
	•	

#### **Information Disclosure Statement**

Commissioner for Patents P.O Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (listed on the attached Form PTO-1449 and attached thereto) of which they are aware, that they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement:

(a) accompanies the new patent application submitted herewith. 37 CFR §1.97(a).
(b) $\square$ is filed within three months after the filing date of the application or within three months after the date of entry into the national stage of a PCT application as set forth in 37 CFR §1.491.
(c) $\square$ as far as is known to the undersigned, is filed before the mailing date of a first Office Action on the merits.

(d) is filed after the first Office Action and more than three months after the application filing date or PCT national stage date of entry filing but, as far

	rejection either the specified Deposi Information	nown to the undersigned, prior to the mailing date of either a final on or a notice of allowance, whichever occurs first, and is accompanied by the fee (\$180.00) set forth in 37 CFR §1.17(p) or a certification as ed in 37 CFR §1.97(e), as checked below. Authorization to charge the Account No. 07-1048 in the amount of \$180.00 to cover the cost of this ation Disclosure Statement is provided in the Transmittal Letter submitted the in duplicate.
	allowar Transm No. 07- as spec	is filed after the mailing date of either a final rejection or a notice of nce, whichever occurred first, and is accompanied by authorization (in the nittal Letter submitted herewith in duplicate) to charge Deposit Account 1048 the fee (\$180.00) set forth in 37 CFR §1.17(I)(1) and a certification cified in 37 CFR §1.97(e), as checked below. This document is to be sered as a petition requesting consideration of the Supplemental ation Disclosure Statement.
[If either of bo	oxes (d	) or (e) is checked above, the following "certification" under 37 CFR
§1.97(e) may	need to	be completed.] The undersigned certifies that:
	counte	Each item of information contained in the Information Disclosure lent was cited in a communication mailed from a foreign patent office in a rpart foreign application not more than three months prior to the filing of ormation Disclosure Statement.
	foreign reason	No item of information contained in this Information Disclosure Statement ed in a communication mailed from a foreign patent office in a counterpart application or, to the knowledge of the undersigned after making able inquiry, was known to any individual designated in 37 CFR §1.56(c) nan three months prior to the filing of this Information Disclosure ent.
us	_, filed _	n Form PTO-1449 is supplied: PCT International Search Report for PCT/ with attached patents and publications.  sone □ only those listed below:
PTO-1449 are a prior applica	not sur	blication(s) which are marked with an asterisk (*) on the attached Form oplied because they were previously cited by or submitted to the Office in the latest process of the state of the open cited by or submitted to the Office in the latest process of the latest p
A concise exp		of relevance of the items listed on PTO-1449 is:
	$\boxtimes$	not given
		given for each listed item

Attorney Docket No. GC637-2 Page 3

	given for only non-English language listed item(s)
•	in the form of an English language copy of a Search Report from a patent office, issued in a counterpart application, which refers to the nt portions of the references.
ICICVA	nt portions of the references.

The Examiner is reminded that a "concise explanation of the relevance" of the submitted prior art "may be nothing more than identification of the particular figure or paragraph of the patent or publication which has some relation to the claimed invention." MPEP §609.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR §1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR §1.97(b), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR §1.56(a) exists. It is submitted that the Information Disclosure Statement is in compliance with 37 CFR §1.98 and MPEP §609 and the Examiner is respectfully requested to consider the listed references.

Respectfully submitted,

Registration No. 43,510

Date: July 30, 2007

Genencor International, Inc. 925 Page Mill Road Palo Alto, CA 94304-1013

Tel: 650 846-7615 Fax: 650 845-6504

### INFORMATION DISCLOSURE CITATION

Attorney Docket No.: GC637-2	OIPE	Serial No.: 09/975,139
Applicant: Schellenberger, et al.	120	
Filing Date: October 10, 2001	AUG 0 2 2007	Group:
Page <u>1</u> of <u>3</u>		Date of this Submission: July 30, 2007

Examiner's	Document				Sub-	Filing
Initial	Number	Date	Name	Class	Class	Date
	4,816,567	3/28/89	Cabilly, et al.			
	5,565,332	10/15/96	Hoogenboom, et al.			
	5,571,698	11/5/93	Ladner			
	5,681,610	11/5/96	Schloesser, et al.			
	5,681,702	10/28/97	Collins, et al.			
	5,698,426	12/16/97	Huse, et al.			
	5,723,323	3/3/98	Kauffman, et al.			
	5,830,721	11/3/98	Stemmer, et al.			
	5,922,545	7/13/99	Matheakis, et al.			
	6,107,059	8/22/00	Hart, et al.			
	6,114,149	9/5/00	Fry, et al.			

# FOREIGN PATENT DOCUMENTS

Examiner's	Document				Sub-	Translation
Initials	Number	Date	Country	Class	Class	Yes/No
	WO92/14843		PCT			
	2,276,169		United Kingdom			
	WO 91/19813		PCT			
	WO 92/05285		PCT			

### OTHER DOCUMENTS

Examiner's Initials	Author, Title, Date, Pertinent Pages, etc.
	Ballinger, Biochemistry 34:13312 (1995). Designing Subtilisin BPN To Cleave Substrates Containing Dibasic Residues.
	Ballinger, Biochemistry 35:13579 (1996). Furilisin: A Variant of Subtilisin BPN' Engineered for Cleaving Tribasic Substrates.
	Berger, et al., Anal Biochem 214:571 (1993). Phoenix Mutagenesis: One-Step Reassembly of Mult ply Cleaved Plasmids with Mixtures of Mutant and Wild-Type Fragments.
	Bock et al., Nature 1992 Feb 6, 355(6360):564-6. Selection of single-stranded DNA molecules that bind and inhibit human thrombin.
	Cao, Technique 2:109 (1990)
	Carotti, Chem Biol Interact 67:171 (1988)). Qsar Analysis of The Subtilisin Hydrolysis of X-Phenyl Hippurates II A. Study of Substilisin BPN.
	Chatellier, et al., Anal. Biochem. 229:282 (1995). Codon-Based Combinatorial Alanine Scanning Site- Directed MutagenesisL Design, Implementation, and Polymerase Chain Reaction Screening.
	Cho, et al., J Mol Biol 297:309 (2000). Constructing High Complexity Synthetic Libraries of Long ORFs Using In Vitro Selection.
	Cote, et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, 1985, p. 77.

Attorney Docket No.: GC637-2	Serial No.: 09/975,139
Applicant: Schellenberger, et al.	
Filing Date: October 10, 2001	Group:
Page <u>2</u> of <u>3</u>	Date of this Submission: July 30, 2007

 Using In Vitro Selection.
Cote, et al. Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, 1985, p. 77.
Cumber et al. (1992) J Immunology 149B:120-126. Comparative Stabilities In Vitro And In Vivo of a Recombinant Mouse Antibody FvCys Fragment and bisFvCys Conjugate
Dahiyat & Mayo, Protein Sci. 5:895 (1996). Protein Design Automation. Protein design automation.
 Dayhoff, et al., Atlas of Protein Sequence and Structure (Natl. Biomed. Res. Found., Washington), Vol. 5,
Suppl. 3, pp. 345-358 (1978)). A Model Of Evolutionary Change in Proteins
Deng, et al., Anal Biochem 200:81 (1992). Site-Directed Mutagenesis Of Virtually Any Plasmid By Eliminating a Unique Site.
Ehrlich et al. (1980) Biochem 19:4091-4096); Isolation of an Active Heavy-Chain Variable Domain From A Homogeneous Rabbit Antibody by Cathepsin B Digestion of the Aminoethylated Heavy Chain.
 Gaytan, et al., Chem Biol 5:519 (1998); Combination of DMT-mononucleotide and Fmoc-Trinucleotide phosphoramidites in oligonucleotide synthesis affords an automatable codon-level mutagensis method.
 Gobel, et al., Proteins 18:309 (1994). Correlated Mutations and Residues Contacts in Proteins.
Goldman & Youvan, Bio/Technology 10:1557 (1992); An Algorithmically optimized combinatorial library screened by digital imaging spectroscopy.
Goldman, et al., Drug Development Research 33:125(1994). Estimating proteins Functions From Combinatorial Sequence Data Using Decision Algorithms and Neutral Networks.
Gribskov (Gribskov, Proc. Nat'l Acad. Sci. USA 84:4355 (1987). Profile analysis: Detection of distantly related proteins.
Haaparanta & Huse, Mol Divers 1:39 (1995)) A Combinatorial method for constructing libraries of long peptides displayed by filamentous phage.
Horton, et al., Gene 77:61 (1989); Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.
 Huang & Santi, Anal Biochem 218:454 (1994); Identification of Biologically Active Mutants by Combinatorial Cassette Mutagenesis: Exclusion of Wild-Type Codon from Degenerate Codons.
 Hubbard, Protein Eng 1:159 (1987) Comparison of solvent –inaccessible cores of homologous proteins: definitions useful of protein modelling.
 Huse et al., Int Rev Immunol. 1993;10(2-3):129-37; Increased Antibody Affinity and Specificity by Codon-Based Mutagenesis
Huston et al. (1988) Proc Natl Acad Sci USA 85:5879-5883); Protein engineering of antibody binding sites: Recovery of specific activity in anti-digoxin single-chain Fv analogue produced in Escherichia coli
Inbar et al. (1972) Proc Natl Acad Sci USA 69:2659-2662. Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains.
 Jensen, et al., Nucleic Acids Res 26:697 (1998) Scoring functions for computational algorithms applicable to the design of spiked oligonucleotides.
 Jespers, et al., J. Mol. Biol. 290:471 (1999). Guiding a Docking Mode by Phage Display: Selection of Correlated Mutations at the Staphylokinase-Plasmin Interface.
Kirkham et al., J Mol Biol. 1999 Jan 22;285(3):909-15). Towards the Design of an Antibody that Reconises a Given Protein Epitope.
 Krogh, "An introduction to Hidden Markov models for biological sequences," in COMPUTATIONAL METHODS IN MOLECULAR BIOLOGY, Salzberg, et al., eds, Elsevier, Amsterdam.
Kunkel, Proc Natl Acad Sci U S A 1985 Jan;82(2):488-92; Rapid and efficient site-specific mutagenesis without phenotypic selection.
 Lahr, et al., Proc. Nat'l Acad. Sci. USA 96:14860 (1999). Patterned library analysis: A Method For The Quantitative assessment of hypotheses concerning the determinants of protein structure.
 Leach et al. (1992) J. Am. Chem. Soc. 114:3675-3683 and Switzer et al., supra.
 Ling & Robinson, Anal Biochem 254:157 (1997)). Approaches to DNA Mutagenesis An Overview
Lockless & Ranganathan, Science 286:295 (1999); Evolutionarily Conserved Pathways of Energetic Connectivity in Protein Families.
Lyttle, et al., Biotechniques 19:274 (1995); Mutagenesis Using Trinucleotides B-Cyanoethyl Phosphoramidites.

Attorney Docket No.: GC637-2	• i	Serial No.: 09/975,139
Applicant: Schellenberger, et al.		
Filing Date: October 10, 2001		Group:
Page3 of3		Date of this Submission: July 30, 2007

Mantsch et al. (1993) Biochem. 14:5593-5601. Structural and Enzymatic Properties of Adenine 1-Oxide Nucleotides.  Needleman & Wunsch, J. Mol. Biol. 48:443 (1970). A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins.  Novere et al. (Biophys. Journal v.76, p. 2329-2345, May 1999. Improved Secondary Structure Predictions for a Nicotinic Receptor Subunit:
Similarities in the Amino Acid Sequence of Two Proteins.  Novere et al. (Biophys. Journal v.76, p. 2329-2345, May 1999. Improved Secondary Structure Predictions
Overington, et al., Protein Sci 1:216 (1992) Environment-specific amino acid substitution tables: Tertiary templated and prediction of protein folds.
Pack et al. (1992) Biochem 31:1579-1584: Miniantibodies:Use of Amphipathic Helices To Produce Functional, Flexibly Linked Dimeric Fv Fragments with High Avidity in Escherichia coli
Pazos, et al., Comput. Appl. Biosci. 13:319 (1997). A graphical interface for correlated mutations and other protein structure prediction methods.
Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988). Improved tools for biological sequence comparison.
Piccirilli et al. (1990) Nature 343:33-37. Enzymatic incorporation of a new base pair into DNA and RNA extends the genetic alphabet.
Riechmann et al. (1988) Nature 332:323-327; Reshaping human antibodies for therapy
Shi, et al., PCR Methods Appl. 3:46 (1993); Rapid PCR Construction of a Gene-Containing Lym-1 Antibody Variable Regions
Smith & Waterman, Adv. Appl. Math. 2:482 (1981) Comparison of Biosequences
Sondek & Shortle Proc. Nat'l Acad. Sci. USA 89:3581 (1992)). A General Strategy for Random Insertion and substitution mutagenesis Substochiometric coupling of trinucleotide phosphoramidites
Switzer et al. (1993) Biochemistry 32:10489-
Thompson, J. D., D. G. Higgins, et al. (1994). Nucleic Acids Res 22(22): 4673-80.]. Clustal W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting position-specific gap penalties and weight matrix choice.
Tomandl, et al., J. CompAided Molec. Design 11: 29 (1997)). Optimizing doped libraries by using genetric algorithms.
Tor et al. (1993) J. Am. Chem. Soc. 115:4461-4467. Site-Specific Enzymatic Incorporation of an Unnatural Base, N6 Isoguanosine, into RNA.
Tuerk et al., Proc Natl Acad Sci U S A 1992 Aug 1, 89(15):6988-92. RNA pseodoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase.
Verhoeyan et al. (1988) Science 239:1534-1536. Reshaping Human Antibodies: Grafting an
Virnekas, et al., Nucl. Acids Res 22:5600 (1994) Trinucleotide phosphoramidites:ideal reagents for the synthesis of mixed oligonucleotides for random mutagenesis.
Winter et al. (1991) Nature 349:293-299. Man-made antibodies
Zoller, Curr Opin Biotechnol 3: 348 (1992) New recombinant DNA methodology for protein engineering
Examiner Date Considered
Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant. PTO-1449